Back to results
US 7,351,707 B2Granted
Spiroazacyclic compounds as monoamine receptor modulators
AssigneeACADIA Pharmaceuticals Inc.
InventorNathalie Schlienger
Life of this patent
Estimating the term…
Abstract
The present invention relates to optionally substituted 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
Claims23
A compound of formula I, salts and stereoisomers thereof
- wherein X is OCH2;
- Y is selected from the group consisting of O and S;
- Z is CH;
- R1 is hydrogen, or an optionally substituted substituent selected from the group consisting of C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, aryl, heteroaryl, aryl(C1-6 alkyl), heteroaryl(C1-6 alkyl), heterocyclyl(C1-6 alkyl), hydroxy(C1-6 alkyl), amino(C1-6 alkyl), and halo(C1-6 alkyl);
- m is 0;
- R4 is absent;
- R5 and R6 are optionally substituted substituents independently selected from the group consisting of aryl(C1-6 alkyl), heteroaryl(C1-6 alkyl), and heterocyclyl(C1-6 alkyl);
- R2 and R3 are independently selected from the group consisting of hydrogen, halogen, hydroxy, and optionally substituted C1-6 alkyl or selected such that R2 and R3 together form a ring system such that
- is selected from the group consisting of
- wherein R7 and R8 are independently selected from the group consisting of hydrogen, halogen, hydroxy, and optionally substituted C1-6 alkyl.
7 more elements
Dependencies are inferred from the claim text.